The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33745547.
- Also identified by DOI 10.1016/j.kint.2020.11.019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The STARMEN trial postulated that in primary membranous nephropathy (pMN) treatment with tacrolimus plus rituximab would be superior to a traditional Ponticelli regimen of alternating cyclophosphamide and glucocorticoids. This was not the case. Significantly more remissions were achieved in cyclophosphamide-treated patients, and more of these were complete remissions. Considering these results with those of the Mentor trial, which compared rituximab with cyclosporine in pMN, we offer an evidence-based perspective on the role of calcineurin inhibition for pMN treatment.
Medical subject headings
- Calcineurin Inhibitors
- Glomerulonephritis, Membranous